JP2024519188A - 含窒素複素環系化合物、その調製方法及びその医薬的応用 - Google Patents
含窒素複素環系化合物、その調製方法及びその医薬的応用 Download PDFInfo
- Publication number
- JP2024519188A JP2024519188A JP2024515728A JP2024515728A JP2024519188A JP 2024519188 A JP2024519188 A JP 2024519188A JP 2024515728 A JP2024515728 A JP 2024515728A JP 2024515728 A JP2024515728 A JP 2024515728A JP 2024519188 A JP2024519188 A JP 2024519188A
- Authority
- JP
- Japan
- Prior art keywords
- group
- general formula
- compound
- salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110565410 | 2021-05-24 | ||
| CN202110565410.0 | 2021-05-24 | ||
| CN202110694022 | 2021-06-22 | ||
| CN202110694022.2 | 2021-06-22 | ||
| CN202110856289.7 | 2021-07-28 | ||
| CN202110856289 | 2021-07-28 | ||
| CN202210198679.4 | 2022-03-02 | ||
| CN202210198679 | 2022-03-02 | ||
| PCT/CN2022/094612 WO2022247816A1 (zh) | 2021-05-24 | 2022-05-24 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519188A true JP2024519188A (ja) | 2024-05-08 |
| JP2024519188A5 JP2024519188A5 (cg-RX-API-DMAC7.html) | 2025-06-03 |
Family
ID=84229501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515728A Pending JP2024519188A (ja) | 2021-05-24 | 2022-05-24 | 含窒素複素環系化合物、その調製方法及びその医薬的応用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240287094A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4349836A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519188A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240012437A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117177971A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022280845A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022496A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219858A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013890A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI926045B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022247816A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI876212B (zh) | 2021-10-01 | 2025-03-11 | 美商辛瑟拉股份有限公司 | 吖丁啶及吡咯啶parp1抑制劑及其用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| PT4497438T (pt) | 2022-04-28 | 2025-10-31 | Xinthera Inc C/O Gilead Sciences Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| EP4524142A4 (en) * | 2022-05-07 | 2026-07-01 | Scibrunch Therapeutics Co Ltd | FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1 |
| WO2024041643A1 (zh) * | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| KR20250103773A (ko) * | 2022-11-23 | 2025-07-07 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법 |
| AU2023412594A1 (en) * | 2022-12-23 | 2025-07-10 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Parp1 inhibitors |
| JP2026524090A (ja) | 2023-06-08 | 2026-07-17 | 上海森▲輝▼医▲葯▼有限公司 | ホルムアミド系化合物の製造方法 |
| CN120677162A (zh) * | 2023-06-13 | 2025-09-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005521698A (ja) * | 2002-03-26 | 2005-07-21 | 藤沢薬品工業株式会社 | 新規な三環式化合物 |
| JP2011500758A (ja) * | 2007-10-26 | 2011-01-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parp阻害剤としてのキノリノン誘導体 |
| WO2021013735A1 (en) * | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
| JP2024514223A (ja) * | 2021-04-19 | 2024-03-28 | シンセラ, インコーポレイテッド | Parp1阻害薬及びその使用 |
| JP2025516367A (ja) * | 2022-05-07 | 2025-05-27 | メッドシャイン ディスカバリー インコーポレイテッド | Parp1を選択的に阻害するフルオロキノキサリノン誘導体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) * | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parpおよびtank阻害剤としてのキノリノン誘導体 |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| TWI693218B (zh) | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光a激酶抑制劑 |
| WO2020098774A1 (zh) * | 2018-11-16 | 2020-05-22 | 江苏恒瑞医药股份有限公司 | 一种包含parp抑制剂的药物组合物 |
| CN116018132A (zh) | 2020-06-24 | 2023-04-25 | Itf研究制药有限公司 | 软明胶胶囊 |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
-
2022
- 2022-05-24 AU AU2022280845A patent/AU2022280845A1/en active Pending
- 2022-05-24 EP EP22810541.7A patent/EP4349836A4/en active Pending
- 2022-05-24 US US18/562,127 patent/US20240287094A1/en active Pending
- 2022-05-24 CN CN202280027629.8A patent/CN117177971A/zh active Pending
- 2022-05-24 TW TW111119308A patent/TWI926045B/zh active
- 2022-05-24 WO PCT/CN2022/094612 patent/WO2022247816A1/zh not_active Ceased
- 2022-05-24 JP JP2024515728A patent/JP2024519188A/ja active Pending
- 2022-05-24 KR KR1020237042926A patent/KR20240012437A/ko active Pending
- 2022-05-24 BR BR112023022496A patent/BR112023022496A2/pt unknown
- 2022-05-24 MX MX2023013890A patent/MX2023013890A/es unknown
- 2022-05-24 CA CA3219858A patent/CA3219858A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005521698A (ja) * | 2002-03-26 | 2005-07-21 | 藤沢薬品工業株式会社 | 新規な三環式化合物 |
| JP2011500758A (ja) * | 2007-10-26 | 2011-01-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parp阻害剤としてのキノリノン誘導体 |
| WO2021013735A1 (en) * | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
| JP2024514223A (ja) * | 2021-04-19 | 2024-03-28 | シンセラ, インコーポレイテッド | Parp1阻害薬及びその使用 |
| JP2025516367A (ja) * | 2022-05-07 | 2025-05-27 | メッドシャイン ディスカバリー インコーポレイテッド | Parp1を選択的に阻害するフルオロキノキサリノン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023022496A2 (pt) | 2024-01-16 |
| CA3219858A1 (en) | 2022-12-01 |
| KR20240012437A (ko) | 2024-01-29 |
| TWI926045B (zh) | 2026-05-21 |
| CN117177971A (zh) | 2023-12-05 |
| EP4349836A4 (en) | 2024-10-30 |
| EP4349836A1 (en) | 2024-04-10 |
| US20240287094A1 (en) | 2024-08-29 |
| WO2022247816A1 (zh) | 2022-12-01 |
| AU2022280845A1 (en) | 2023-12-14 |
| TW202313630A (zh) | 2023-04-01 |
| MX2023013890A (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4361157A1 (en) | Fused tetracyclic compound, preparation method therefor and application thereof in medicine | |
| CN115368383A (zh) | 稠合含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| KR20240012437A (ko) | 질소 함유 헤테로사이클릭 화합물, 이의 제조 방법 및 의학에서 이의 응용 | |
| CN115605479B (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| CN119365465A (zh) | 稠环类化合物、其制备方法及其在医药上的应用 | |
| CN117203207A (zh) | 桥环类化合物、其制备方法及其在医药上的应用 | |
| CN115385937A (zh) | 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用 | |
| JP7781059B2 (ja) | ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用 | |
| CN120365289A (zh) | 稠环类化合物、其制备方法及其在医药上的应用 | |
| CN114907377A (zh) | 稠合四环类化合物、其制备方法及其在医药上的应用 | |
| WO2024046420A1 (zh) | 稠合二环类化合物、其制备方法及其在医药上的应用 | |
| CN112996783A (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| WO2024041643A1 (zh) | 稠合三环类化合物、其制备方法及其在医药上的应用 | |
| CN115867552B (zh) | 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| CN113912608B (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 | |
| CN113004303A (zh) | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 | |
| CN113135942B (zh) | 稠合嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| EA051431B1 (ru) | Азотсодержащее гетероциклическое соединение, способ его получения и его применение в качестве ингибитора parp1 | |
| CA3300208A1 (en) | Heteroaryl compound, preparation method therefor, and use thereof in medicine | |
| WO2021143821A1 (zh) | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| HK40070277A (en) | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof | |
| HK40070277B (en) | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof | |
| CN114907406A (zh) | 嘧啶衍生物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250526 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250526 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260528 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260721 |